The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 14, 2025
Filed:
Nov. 16, 2021
Applicant:
Novartis Ag, Basel, CH;
Inventors:
Guido Junge, Basel, CH;
Michael Kiffe, Efringen-Kirchen, DE;
Jiri Kovarik, Zurich, CH;
Richard Stein, Weil am Rhein, DE;
Frank Waldron-Lynch, Brookline, MA (US);
Assignee:
NOVARTIS AG, Basel, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 37/00 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01);
U.S. Cl.
CPC ...
C07K 16/245 (2013.01); A61K 45/06 (2013.01); A61P 37/00 (2018.01); C07K 16/2875 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01);
Abstract
The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof for use in the treatment or for use in alleviating the symptoms of an NLRC4 inflammasomopathy, such as an NLRC4-GOF inflammasomopathy in a subject in need thereof. This invention also relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof for use in the treatment or for use in alleviating the symptoms of AIFEC in a subject in need thereof.